M L Berger
Affiliation: Merck Research Laboratories
- The once and future application of cost-effectiveness analysisM L Berger
Merck and Company, Inc, West Point, PA 19486 0004, USA
Jt Comm J Qual Improv 25:455-61. 1999..However, it must be embedded within a framework that promotes confidence in the social justice of health care decision making through ongoing dialogue about how the value of health and health care are defined...
- Investing in healthy human capitalMarc L Berger
USHH Outcomes Research and Management, Merck and Co, Inc, West Point, PA 19486 0004, USA
J Occup Environ Med 45:1213-25. 2003..We believe that employers who increase their investments in healthy human capital now will emerge tomorrow as the companies leading the gains in US productivity...
- Efficient patient identification strategies for women with osteoporosisT A Abbott
Outcomes Research and Management, Merk and Co, West Point, PA 19486, USA
J Clin Densitom 2:223-30. 1999..In choosing among the efficient strategies, decision makers must determine the extent to which they are willing to trade off higher program cost for greater sensitivity...
- The decision to conduct a head-to-head comparative trial: a game-theoretic analysisEdward C Mansley
Outcomes Research and Management, Merck and Co Inc, WP39 166, P O Box 4, West Point, PA 19486 000, USA
Med Decis Making 27:364-79. 2007..Finally, the results indicate that incentives that offset the direct cost of a trial can prevent a no-trial equilibrium, even when both firms face the possibility of an inferior outcome...
- Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilizationPamela B Landsman
Outcomes Research and Management, US Medical and Scientific Affairs, Merck and Company Inc, PO Box 100, UG2B 74, 351 N Sumneytown Pike, North Wales, PA 19454 2505, USA
Am J Manag Care 11:621-8. 2005..To estimate responsiveness of prescription demand within 9 therapeutic classes to increased cost-sharing compared with constant cost-sharing...
- Evidence synthesis and evidence-based decision making: related but distinct processesSteven M Teutsch
Merck and Co, Inc, West Point, PA 19486, USA
Med Decis Making 25:487-9. 2005
- Comparative effectiveness: asking the right questions, choosing the right methodSteven M Teutsch
Merck and Company Inc, West Point, Pennsylvania, USA
Health Aff (Millwood) 24:128-32. 2005..We consider the consequences of these strategies. This paper proposes a framework for using different methods to assess available evidence. We contend that choosing the appropriate method can occur only when there are clear policy goals...
- Reliability and validity of the Stanford Presenteeism ScaleRobin S Turpin
USHH Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania 19486 0004, USA
J Occup Environ Med 46:1123-33. 2004..This study reports the reliability and validity of the 13-item Stanford Presenteeism Scale (SPS). The SPS differs from similar scales by focusing on knowledge-based and production-based workers...
- Asthma control and patient satisfaction among early pediatric users of montelukastSiva Narayanan
Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania 19486, USA
J Asthma 39:757-65. 2002..To assess asthma control and patient satisfaction among pediatric users of montelukast in a clinical practice setting...
- Cost-effectiveness analysis: from science to applicationMarc L Berger
Outcomes Research and Management, Merck and Co, Inc, West Point, Pennsylvania 198486, USA
Med Care 43:49-53. 2005..Specifically, how should we balance the desires for equity, universal access to healthcare services and technology, and the right of individuals to secure the specific healthcare resources they want?..
- Alternative valuations of work loss and productivityM L Berger
Department of Outcomes Research and Management, Merck and Co, Inc, 770 Sumneytown Pike WP-39-162, West Point, PA 19486, USA
J Occup Environ Med 43:18-24. 2001..Finally, we offer an agenda for further research...
- Growth in use of lipid-lowering therapies: are we targeting the right patients?Robert W Dubois
Zynx Health, Inc, Beverly Hills, California 90212, USA
Am J Manag Care 8:862-7. 2002..Concern exists that industry marketing has led to increased use of medications by patients with marginal indications...
- A randomized controlled open trial of population-based disease and case management in a Medicare Plus Choice health maintenance organizationDavid C Martin
Coventry Health Care, Inc, PA, USA
Prev Chronic Dis 1:A05. 2004....
- How to present the business case for healthcare quality to employersSean Nicholson
Cornell University, Ithaca, New York 14853, USA
Appl Health Econ Health Policy 4:209-18. 2005....
- Stanford presenteeism scale: health status and employee productivityCheryl Koopman
Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305 5718, USA
J Occup Environ Med 44:14-20. 2002..Further validation of the SPS-6 on actual presenteeism (work loss data) or health status (health risk assessment or utilization data) is needed...
- Valuing reductions in on-the-job illness: 'presenteeism' from managerial and economic perspectivesMark V Pauly
Health Care Systems Department, The Wharton School, University of Pennsylvania, Philadelphia, PA, USA
Health Econ 17:469-85. 2008....
- A general model of the impact of absenteeism on employers and employeesMark V Pauly
Health Care Systems Department, The Wharton School, 3641 Locust Walk, Philadelphia, PA 19104 6218, USA
Health Econ 11:221-31. 2002..In the long run, workers are likely to bear much of the incidence of the costs associated with absenteeism, and therefore be the likely beneficiaries of any reduction in absenteeism...
- Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysisJohn R Wingard
University of Florida College of Medicine, Gainesville, 32610, USA
Clin Ther 27:960-9. 2005..7% and 62.8% of patients, respectively) and exhibited a generally better safety profile, particularly with respect to impaired renal function (IRF) (P = 0.02)...
- Measuring the effects of work loss on productivity with team productionSean Nicholson
Department of Policy Analysis and Management, Cornell University, Ithaca, NY 14853, USA
Health Econ 15:111-23. 2006..The median multiplier is 1.28, which supports the view that the cost to the firm of missed work is often greater than the wage...
- The assessment of chronic health conditions on work performance, absence, and total economic impact for employersJames J Collins
The Dow Chemical Company, Midland, Michigan, USA
J Occup Environ Med 47:547-57. 2005..The objective of this study was to determine the prevalence and estimate total costs for chronic health conditions in the U.S. workforce for the Dow Chemical Company (Dow)...
- A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugsJoshua J Ofman
Southern California Evidence Based Practice Center, Department of Medicine, Cedars Sinai Health System, Beverly Hills 90212, USA
J Rheumatol 29:804-12. 2002..We synthesized the published and unpublished evidence to determine the least biased estimates of the risks of perforations, ulcers, and bleeds (PUB) associated with NSAID use from all study designs and all languages...
- Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitionsWalter L Straus
AHCPR Southern California Evidence Based Practice Center, Los Angeles, California, USA
Am J Gastroenterol 97:1951-8. 2002..Using alternative definitions, we assessed the relationship between NSAID use and dyspepsia...
- Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugsJoshua J Ofman
Cedars Sinai Health System and Zynx Health Inc, Los Angeles, California 90212, USA
Arthritis Rheum 49:508-18. 2003..Using published and unpublished data sources, we sought to determine estimates of the risks of dyspepsia associated with NSAIDs...
- Rational formulary decision making: is drug classification rational?Marc L Berger
Value Health 6:175-6. 2003
- Aligning quality for populations and patients: do we know which way to go?Erica Ilene Lubetkin
Department of Community Health and Social Medicine, City University of New York Medical School, New York, NY 10031, USA
Am J Public Health 93:406-11. 2003..Such a creation would amount to a whole that is stronger than the sum of the component parts...
- Do disease management programs for patients with coronary heart disease make a difference? Experiences of nine practicesMary N Walsh
Northside Cardiology, Indianapolis, Ind, USA
Am J Manag Care 8:937-46. 2002..To observe the experience of 9 practice sites in implementing provider-defined disease management programs for coronary heart disease patients...